Citations

Clear

1011 citation(s) found for "Barry, WT".

The heavy heart of HFpEF
Borlaug, Barry A. , Maleszewski, Joseph J. , Borlaug, Barry A

Mayo Clinic

European Heart Journal | May 18, 2020 | Volume: 41 | Issue: 36 | Pages: 3447-3447

10.1093/eurheartj/ehaa478 | PMID 32638013 Get It

Proposal for Coronavirus Disease 2019 Management
Downs, John B. , Weled, Barry J., Räsänen, Jukka, Haines, Krista , Vidyasagar, Dharmapuri, Stock, M., Habashi, Nader M.

Mayo Clinic

Critical Care Explorations | May 15, 2020 | Volume: 2 | Issue: 5 | Pages: e0127

10.1097/cce.0000000000000127 | PMID 32671351 Get It

Setting: The coronavirus disease 2019 pandemic has raised fear throughout the nation. Current news and social media predictions of ventilator, medication, and personnel shortages are rampant. Patients: Patients with coronavirus disease 2019 are presenting with early respiratory distress and hypoxemia, but not hypercapnia. Interventions: Patients who maintain adequate alveolar ventilation, normocapnia, and adequate oxygenation may avoid the need for tracheal intubation. Facemask continuous positive airway pressure has been used to treat patients with respiratory distress for decades, including those with severe acute respiratory syndrome. Of importance, protocols were successful in protecting caregivers from contracting the virus, obviating the need for tracheal intubation just to limit the spread of potentially infectious particles. Conclusions: During a pandemic, with limited resources, we should provide the safest and most effective care, while protecting caregivers. Continuous positive airway pressure titrated to an effective level and applied early with a facemask may spare ventilator usage. Allowing spontaneous ventilation will decrease the need for sedative and paralytic drugs and may decrease the need for highly skilled nurses and respiratory therapists. These goals can be accomplished with devices that are readily available and easier to obtain than mechanical ventilators, which then can be reserved for the sickest patients.
Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction
Redouane, Brahim, Greene, Stephen J. , Fudim, Marat , Ambrosy, Andrew P. , Sun, Jie‐Lena , McNulty, Steven E., Mentz, Robert J. , Felker, G. Michael , Cooper, Lauren B. , Sharma, Abhinav , Mentz, Robert J , Vaduganathan, Muthiah , DeVore, Adam D. , Hernandez, Adrian F. , Borlaug, Barry A. , Velazquez, Eric J. , Margulies, Kenneth B.

Mayo Clinic

Circulation: Heart Failure | May 4, 2020 | Volume: 13 | Issue: 5 | Pages: No page available

10.1161/circheartfailure.119.006758 | PMID 32362166 Get It

Background: The FIGHT (Functional Impact of GLP-1 [glucagon-like peptide-1] for Heart Failure Treatment) trial randomized 300 patients with heart failure with reduced ejection fraction (HFrEF) and a recent hospitalization for heart failure to liraglutide versus placebo. While there was no difference in the primary outcome (rank score of time to death, time to rehospitalization for heart failure, and change in NT-proBNP [N-terminal pro-B-type natriuretic peptide]), there was a significant increase in cystatin C among patients randomized to liraglutide raising concern of adverse renal outcomes. We performed a post hoc analysis of FIGHT to investigate whether liraglutide was associated with worsening renal function (WRF). Methods: The relationship between randomization to liraglutide and WRF was evaluated using logistic regression models. Two hundred seventy-four patients (91%) had complete data to assess for WRF defined as: increase in SCr ≥0.3 mg/dL, or ≥25% decrease in estimated glomerular filtration rate, or an increase in cystatin C ≥0.3 mg/L from baseline to 180-days. Results: Patients with WRF (n=113, 41%), compared with those without, were older, had more comorbidities, and lower utilization of guideline-directed medical treatment. Logistic regression models showed that age and baseline cystatin C levels were associated with WRF. In adjusted models, liraglutide was not associated with excess risk of WRF compared with placebo (odds ratio, 1.02 [95% CI, 0.62–1.67]). There was also no difference in the rank score when WRF was added as a fourth-tier outcome. Conclusions: Liraglutide was not associated with WRF among patients with HFrEF and a recent hospitalization for heart failure. These data support the relative renal safety profile of liraglutide among patients with HFrEF. Registration: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01800968.
Response by Latif et al to Letter Regarding Article, "Stent-Only Versus Adjunctive Balloon Angioplasty Approach for Saphenous Vein Graft Percutaneous Coronary Intervention: Insights From DIVA Trial"
Latif, Faisal , Uyeda, Lauren , Edson, Robert , Bhatt, Deepak L. , Goldman, Steven , Holmes, David R. , Shunk, Kendrick , Aggarwal, Kul, Bolad, Islam, McFalls, Edwards, Irimpen, Anand, Truong, Huu Tam, Kinlay, Scott , Velagaleti, Raghava S. , Rangan, Bavana V. , Mavromatis, Kreton , Shih, Mei-Chiung , Bhatt, Deepak L , Rao, Sunil V. , Uretsky, Barry F. , Ziada, Khaled M. , Papademetriou, Vasilios , Banerjee, Subhash , Brilakis, Emmanouil S.

Mayo Clinic

Circulation: Cardiovascular Interventions | April 13, 2020 | Volume: 13 | Issue: 4 | Pages: No page available

10.1161/circinterventions.120.009174 | PMID 32279564 Get It

Energetic Adaptations and Stress Reserve in the Obese Heart
Borlaug, Barry A. , Borlaug, Barry A , Malloy, Craig R.

Mayo Clinic

Circulation | April 6, 2020 | Volume: 141 | Issue: 14 | Pages: 1164-1167

10.1161/circulationaha.120.045259 | PMID 32250704 Get It

Disruption of Glycogen Utilization Markedly Improves the Efficacy of Carboplatin against Preclinical Models of Clear Cell Ovarian Carcinoma
Khan, Tashbib , He, Yaowu , Kryza, Thomas , Harrington, Brittney S. , Gunter, Jennifer H. , Sullivan, Mitchell A. , Cuda, Tahleesa , Rogers, Rebecca F. , Davies, Claire M. , Broomfield, Amy, Gough, Madeline , Wu, Andy , McGann, Thomas , Weroha, S. John , Forbes, Josephine M. , Armes, Jane E., Barry, Sinead , Coward, Jermaine , Jagasia, Nisha , Snell, Cameron , Hooper, John D. , Wu, Andy C , Haluska, Paul , Forbes, Josephine M , Hooper, John D , Rogers, Rebecca, Chetty, Naven , Lourie, Rohan , Perrin, Lewis C

Mayo Clinic

Cancers | April 3, 2020 | Volume: 12 | Issue: 4 | Pages: 869

10.3390/cancers12040869 | PMID 32260077 Get It

High stage and recurrent ovarian clear cell carcinoma (OCC) are associated with poor prognosis and resistance to chemotherapy. A distinguishing histological feature of OCC is abundant cytoplasmic stores of glucose, in the form of glycogen, that can be mobilized for cellular metabolism. Here, we report the effect on preclinical models of OCC of disrupting glycogen utilization using the glucose analogue 2-deoxy-D-glucose (2DG). At concentrations significantly lower than previously reported for other cancers, 2DG markedly improves the efficacy in vitro of carboplatin chemotherapy against chemo-sensitive TOV21G and chemo-resistant OVTOKO OCC cell lines, and this is accompanied by the depletion of glycogen. Of note, 2DG doses—of more than 10-fold lower than previously reported for other cancers—significantly improve the efficacy of carboplatin against cell line and patient-derived xenograft models in mice that mimic the chemo-responsiveness of OCC. These findings are encouraging, in that 2DG doses, which are substantially lower than previously reported to cause adverse events in cancer patients, can safely and significantly improve the efficacy of carboplatin against OCC. Our results thus justify clinical trials to evaluate whether low dose 2DG improves the efficacy of carboplatin in OCC patients.
Towards Estimation of Three-Dimensional Knee Rotations
McPherson, April L. , Felton, Christopher L. , Hale, Rena F. , Gilbert, Barry K., Schilaty, Nathan D. , Hewett, Timothy E. , Holmes, David R. , Haider, Clifton R. , Schilaty, Nathan D , Felton, Christopher L

Mayo Clinic

2019 53rd Asilomar Conference on Signals, Systems, and Computers | March 31, 2020 | Volume: No volume available | Issue: No issue available | Pages: 1359-1363

10.1109/ieeeconf44664.2019.9048749 Get It

Targeting Pulmonary Capillary Permeability to Reduce Lung Congestion in Heart Failure: A Randomized, Controlled Pilot Trial
Stewart, Glenn M. , Johnson, Bruce D. , Sprecher, Dennis L. , Reddy, Yogesh N.V. , Obokata, Masaru , Goldsmith, Steven R., Барт, Б. Я., Oughton, Anna, Fillmore, Christina, Behm, David J., Bart, Bradley A. , Nishimura, Rick , Obokata, Masaru , Borlaug, Barry A.

Mayo Clinic

European Journal of Heart Failure | March 30, 2020 | Volume: 22 | Issue: 9 | Pages: 1641-1645

10.1002/ejhf.1809 | PMID 32227554 Get It

Abstract Aims Lung congestion in patients with heart failure (HF) has traditionally been treated using interventions that reduce pulmonary capillary hydrostatic pressure. The transient receptor potential vanilloid 4 (TRPV4) channel regulates fluid transit across the pulmonary capillary-interface, and represents a novel target to reduce lung water, independent of pulmonary capillary hypertension. This pilot study examined the safety and potential efficacy of TRPV4 blockade as a novel treatment for HF. Methods and results In this randomized, double-blind, placebo-controlled crossover pilot trial, 11 subjects with chronic, compensated HF were treated with a novel TRPV4 antagonist (GSK2798745) or placebo. The primary endpoint was lung diffusing capacity for carbon monoxide (DLCO) after 7 days of treatment with GSK2798745 as compared to placebo. Secondary endpoints included additional diffusion parameters, spirometry and safety assessments. Compared to placebo, treatment with GSK2798745 resulted in a trend to improvement in DLCO (placebo: −0.336 mL/mmHg/min; GSK2798745: +0.458 mL/mmHg/min; treatment difference: +0.793 mL/mmHg/min; 95% confidence interval: −0.925 to 2.512) that was not statistically significant. GSK2798745 was well-tolerated with no serious adverse events. Conclusion In this pilot trial, GSK2798745 was found to be safe and well-tolerated, with a trend toward improved gas transfer. Further investigation is warranted in larger studies to determine whether treatment with TRPV4 antagonists or alternative treatments targeting capillary permeability might be effective to improve lung congestion, pulmonary gas transfer and clinical status in patients with acute or chronic HF.